Molecular action of metformin in hepatocytes: An updated insight

Current Diabetes Reviews

Volumn 11, Issue 3, 2015, Pages 175-181

  Sliwinska, Agnieszka ^a   Drzewoski, Jozef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amp activated protein kinase; Cyclase adenylate; Gluconeogenesis; Metformin; Mitochondrial glycerophosphate dehydrogenase; Respiratory complex I

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LACTATE DEHYDROGENASE; LACTIC ACID; METFORMIN; PROTEIN KINASE C; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SIRTUIN 1; ANTIDIABETIC AGENT; DIHYDROXYACETONE PHOSPHATE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE;

ANTIDIABETIC ACTIVITY; ARTICLE; CELL STRESS; CITRIC ACID CYCLE; CONFORMATIONAL TRANSITION; CYTOSOL; DRUG ACCUMULATION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE INDUCTION; GLUCONEOGENESIS; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; LIVER CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SUBMITOCHONDRIAL PARTICLE; DRUG EFFECTS; LIVER MITOCHONDRION; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; DIHYDROXYACETONE PHOSPHATE; ELECTRON TRANSPORT COMPLEX I; GLUCONEOGENESIS; GLYCEROLPHOSPHATE DEHYDROGENASE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; METFORMIN; MITOCHONDRIA, LIVER; PYRUVIC ACID;

EID: 84931836592     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811666150325233108     Document Type: Article

References (75)

1. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-67.
2. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-9.
3. Radziuk J, Zhang Z, Wiernsperger N, Pye S. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 1997; 46: 1406-13.
4. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510: 542-6.
5. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-60.
6. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355-69.
7. American Diabetes Association. Standards of Medical care in Diabetes 2015; 2015; 38: (suppl 1) S41-S48.
8. Goldberg R, Temprosa M, Otvos J, et al. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab 2013; 98: 3989-98.
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
10. Holman RC, Paul SK, Bethel MA. Matthews DR, Neil H. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl J Med 2008; 359: 1577-89.
11. Fitch K, Abbara S, Lee H, Stavrou E, Sacks R, Michel T, Hemphill L, Torriani M, Grinspoon S. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS 2012; 26: 587-97.
12. Van Wagner L,B, Rinnela ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011; 4: 249-63.
13. Daniele G, Abdul-Ghani M, DeFronzo RA. What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 2014; 15: 2003-18.
14. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003; 26: 977-80.
15. Beck E, Scheen A. Metformin, an antidiabetic molecule with anticancer properties. Rev Med Lieg. 2013; 68: 444-9.
16. Rena G, Pearson ER, Sakamoto K:Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013; 56: 1898- 906.
17. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-31.
18. Nies A., Koepsell H., Damme K., Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011; 201: 105-67
19. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24: 49-57.
20. Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 2014; 462: 475-87.
21. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348: 607-14.
22. Schafer HJ, Mainka L, Rathgeber G, Zimmer G. Photoaffinity cross-linking of oligomycin-sensitive ATPase from beef heart mitochondria by 3ʹ-arylazido-8-azido ATP. Biochem Biophys Res Commun 1983; 111: 732-9.
23. Lamhonwah AM, Tein I. Novel localization of OCTN1, an organic cation/carnitine transporter, to mammalian mitochondria. Biochem Biophys Res Commun 2006; 345: 1315-25.
24. Shitara Y, Nakamichi N, Norioka M, Shima H, Kato Y, Horie T. Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. Toxicol Sci 2013; 132: 32-42.
25. Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest. 2010; 120: 2267-70.
26. Garrett & Grisham. Biochemistry. Brooks/Cole 2010; pp 598-611.
27. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, Leverve XM. The ROS production induced by a reverseelectron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 2006; 38: 33-42.
28. Taylor SI, Mukherjee C, Jungas RL. Regulation of pyruvate dehydrogenase in isolated rat liver mitochondria. Effects of octanoate, oxidation-reduction state, and adenosine triphosphate to adenosine diphosphate ratio. J Biol Chem 1975; 250: 2028-35.
29. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122: 253-70.
30. Logie L, Harthill J, Patel K, et al. Cellular responses to the metalbinding properties of metformin. Diabetes 2012; 61: 1423-33.
31. Larsen S, Rabøl R, Hansen CN, Madsbad S, Helge JW, Dela F. Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration. Diabetologia 2012; 55: 443-9.
32. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013; 4: 2192.
33. Cao J, Meng S, Chang E, et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem 2014; 289: 20435-46.
34. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.
35. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-62.
36. Sanz P. AMP-activated protein kinase: structure and regulation. Curr Protein Pept Sci 2008; 9: 478-92.
37. Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009; 196: 81-98.
38. Oakhill JS, Steel R, Chen ZP, et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011; 332: 1433-5.
39. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-6.
40. Meng S, Cao J, He Q, et al. Metformin Activates AMP-activated Protein Kinase by Promoting Formation of the αβγ Heterotrimeric Complex. J Biol Chem 2015; 290: 3793-802.
41. Xiao B, Sanders MJ, Underwood E, et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011; 472: 230-3.
42. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 2006; 281: 32207-16.
43. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 2011; 12: 141-51.
44. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005; 437: 1109-11.
45. Dentin R, Liu Y, Koo SH, et al. 3rd, Montminy M. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 2007; 449: 366-9.
46. Dentin R, Hedrick S, Xie J, Yates J, 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science 2008; 319: 1402-5.
47. Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol 2010; 205: 97-106.
48. Liu Y, Dentin R, Chen D, et al. 3rd, Olefsky J, Guarente L, Montminy M. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008; 456: 269-73.
49. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137: 635-46.
50. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008; 57: 306-14.
51. Lee JM, Seo WY, Song KH, et al. AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner. J Biol Chem 2010; 285: 32182-91.
52. Takashima M, Ogawa W, Hayashi K, et al. Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes 2010; 59: 1608-15.
53. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51: 2420-5.
54. Rodgers RL. Glucagon and cyclic AMP: time to turn the page? Curr Diabetes Rev 2012; 8: 362-81.
55. Wakelam M, Murphy GJ, Hruby VJ, Houslay MD. Activation of two signal-transduction systems in hepatocytes by glucagon. Nature 1986; 323: 68-71.
56. Corvera S, Hernandez-Sotomayor SM, Garcia-Sainz JA. Modulation by thyroid status of cyclic AMP-dependent and Ca2+- dependent mechanisms of hormone action in rat liver cells. Possible involvement of two different transduction mechanisms in alpha 1-adrenergic action. Biochim Biophys Acta 1984; 803: 95-105.
57. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-4.
58. Oshima R, Yamada M, Kurogi E, et al. Evidence for organic cation transporter-mediated metformin transport and 5'-adenosine monophosphate- activated protein kinase activation in rat skeletal muscles. Metabolism 2015; 64: 296-304.
59. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMPactivated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-81.
60. Song Y, Shi J, Wu Y, et al. Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3. Chin Med J (Engl) 2014; 127: 1523-9.
61. Matthaei S, Reibold JP, Hamann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin- induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 1993; 133: 304-11.
62. Molloy AM, Ardill J, Tomkin GH.The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 1980; 19: 93-6.
63. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-94.
64. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 2004; 17: 336-42.
65. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005; 22: 654-7.
66. Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes. Diabet Med 2009; 26: 649-54.
67. Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006; 547: 192-9.
68. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-8.
69. Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon- like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002; 298: 779-84.
70. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagonlike peptide-1 from the intestinal L cell. Endocrinology 2011; 152: 4610-9.
71. Foretz M, Ancellin N, Andreelli F, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005; 54: 1331-9.
72. Yang W, Hong YH, Shen XQ, Frankowski C, Camp HS, Leff T. Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem 2001; 276: 38341-4.
73. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulinresistant human HepG2 cells. J Biol Chem 2004; 279: 47898-905.
74. Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulinsensitizing effects of metformin. Nat Med 2013; 19: 1649-54.
75. Kim E, Liu NC, Yu IC, et al. Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes 2011; 60: 1493-503.